Rituximab is a CD20-targeted monoclonal antibody that binds to CD20 molecules and kills tumor B-cells through antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Here, MS4A1 is linked to neoplasm.